N((2,6 dichloro-3-methylphenyl)diphenyl)methylimidazole | 228544-93-2

• 分子结构分类: 有机化合物 - 苯类化合物 - 三苯基化合物
• 英文名称: N((2,6 dichloro-3-methylphenyl)diphenyl)methylimidazole
• 英文别名: 1-[(2,6-Dichloro-3-methylphenyl)-diphenylmethyl]imidazole
• CAS: 228544-93-2
• 化学式: C₂₃H₁₈Cl₂N₂
• 分子量: 393.315
• InChiKey: CWVCCSVZFZPURY-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  6
• 重原子数：
  27
• 可旋转键数：
  4
• 环数：
  4.0
• sp3杂化的碳原子比例：
  0.09
• 拓扑面积：
  17.8
• 氢给体数：
  0
• 氢受体数：
  1

反应信息

• 作为产物：
  描述：

  咪唑 、 (2,6-dichloro-3-methylphenyl)diphenylmethanol 以 溶剂黄146 为溶剂， 以0.40 g (87%)的产率得到N((2,6 dichloro-3-methylphenyl)diphenyl)methylimidazole
  参考文献：
  名称：

  Treatment of GLC1A glaucoma with non-steroidal glucocorticoid antagonists

  摘要：

  非甾体糖皮质激素拮抗剂的组合物，用于治疗GLC1A型青光眼的方法已被披露。

  公开号：

  US06051573A1

文献信息

• Glucocorticoid blocking agents for increasing blood-brain barrier permeability
  申请人：——

  公开号：US20020065259A1

  公开（公告）日：2002-05-30

  Glucocorticoid blockers, including glucocorticoid receptor antagonists, are effective to prevent glucocorticoid-induced decrease in permeability of the blood-brain barrier and to increase the permeability of the blood-brain barrier. Administration of glucocorticoid blockers, including glucocorticoid receptor antagonists, concomitant with administration of drugs for treating diseases of the central nervous system increases delivery of such drugs into the central nervous system.

  糖皮质激素受体阻滞剂，包括糖皮质激素受体拮抗剂，可有效防止糖皮质激素引起的血脑屏障通透性降低，并增加血脑屏障的通透性。在服用治疗中枢神经系统疾病的药物的同时服用糖皮质激素阻断剂，包括糖皮质激素受体拮抗剂，可增加这些药物进入中枢神经系统的剂量。
• Methods for preventing antipsychotic-induced weight gain
  申请人：Corcept Therapeutics, Inc.

  公开号：US20030027802A1

  公开（公告）日：2003-02-06

  This invention generally pertains to the field of psychiatry. In particular, this invention pertains to the discovery that agents capable of inhibiting the binding of cortisol to its receptors can be used in methods for preventing antipsychotic-induced weight gain. Mifepristone, a potent specific glucocorticoid receptor antagonist, can be used in these methods. The invention also provides a kit for preventing AP-induced weight gain in a human including a glucocorticoid receptor antagonist and instructional material teaching the indications, dosage and schedule of administration of the glucocorticoid receptor antagonist.

  本发明一般涉及精神病学领域。特别是，本发明涉及发现能够抑制皮质醇与其受体结合的制剂可用于防止抗精神病药物引起的体重增加的方法。米非司酮是一种强效的特异性糖皮质激素受体拮抗剂，可用于这些方法中。本发明还提供了一种用于预防 AP 诱导的人体体重增加的试剂盒，包括一种糖皮质激素受体拮抗剂和教导糖皮质激素受体拮抗剂的适应症、剂量和给药计划的说明书。
• Methods for inhibiting cognitive deterioration in adults with down's syndrome
  申请人：Corcept Therapeutics, Inc.

  公开号：US20030064974A1

  公开（公告）日：2003-04-03

  This invention generally pertains to the field of psychiatry. In particular, this invention pertains to the discovery that agents capable of inhibiting the binding of cortisol to its receptors can be used in methods for preventing or reversing cognitive deterioration in adults with Down's syndrome. Mifepristone, a potent specific glucocorticoid receptor antagonist, can be used in these methods. The invention also provides a kit for preventing or reversing cognitive deterioration in a DS patient including a glucocorticoid receptor antagonist and instructional material teaching the indications, dosage and schedule of administration of the glucocorticoid receptor antagonist.

  本发明一般涉及精神病学领域。特别是，本发明涉及发现能够抑制皮质醇与其受体结合的制剂可用于预防或逆转患有唐氏综合征的成年人认知功能退化的方法。米非司酮是一种强效的特异性糖皮质激素受体拮抗剂，可用于这些方法中。本发明还提供了一种用于预防或逆转唐氏综合征患者认知功能退化的试剂盒，包括一种糖皮质激素受体拮抗剂和教导糖皮质激素受体拮抗剂的适应症、剂量和给药计划的指导材料。
• Methods for increasing the therapeutic response to electroconvulsive therapy
  申请人：CORCEPT Therapeutics, Inc.

  公开号：US20040029849A1

  公开（公告）日：2004-02-12

  This invention generally pertains to the field of psychiatry. In particular, this invention pertains to the discovery that agents which inhibit the binding of cortisol to the glucocorticoid receptor can be used in methods of increasing the therapeutic response to electroconvulsive therapy (“ECT”).

  本发明一般涉及精神病学领域。特别是，本发明涉及发现抑制皮质醇与糖皮质激素受体结合的制剂可用于提高电休克疗法（"ECT"）治疗反应的方法。
• Methods for treating migraine
  申请人：Corcept Therapeutics, Inc.

  公开号：US20040132703A1

  公开（公告）日：2004-07-08

  This invention relates to the discovery that agents capable of inhibiting the biological action of the glucocorticoid receptor can be used in methods for treating migraine in a subject.

  本发明涉及发现能够抑制糖皮质激素受体生物作用的制剂可用于治疗受试者偏头痛的方法。